Vineet Laboratories Ltd (VINEETLAB) — shareholding pattern, promoter holding, financials and share price
About Vineet Laboratories Ltd (VINEETLAB)
Vineet Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VINEETLAB and on the BSE under scrip code 543298. Its ISIN is INE505Y01010.
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
Vineet Laboratories Limited specializes in the manufacture of drug intermediates and bulk drugs, vital components for active pharmaceutical ingredients (APIs).
Its state-of-the-art facility boasts a versatile setup with stainless steel and glass-lined reactors, suited for varying batch sizes and specialized in handling pyrophoric chemicals like n-Butyl Lithium.
Listed peers in Pharmaceuticals: Phaarmasia Ltd, Asston Pharmaceuticals Ltd, Ajooni Biotech Ltd, Vasundhara Rasayans Ltd, Biofil Chemicals & Pharmaceuticals Ltd, Bacil Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹31.95 a share on 10 Jul 2026, Vineet Laboratories Ltd (VINEETLAB) was valued at a price-to-earnings ratio of -6.16x against an industry P/E of 36.41x and a price-to-book of 4.19x on a book value of ₹7.63 per share as of Mar 2025. Solomo computes return on equity of -69.29% and return on capital employed of -11.23% from filed results. Earnings ratios use standalone results for the twelve months Mar 2025 to Dec 2025.
- P/E
- -6.16x
- Industry P/E
- 36.41x
- P/B
- 4.19x
- EPS (TTM)
- ₹-5.28
- Book value / share
- ₹7.63
- ROE
- -69.29%
- ROCE
- -11.23%
- ROA
- -10.74%
- Debt / equity
- 2.73x
- Dividend yield
- 0%
- EBITDA margin
- -6.59%
- 52-week range
- ₹24.56 – ₹43.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Vineet Laboratories Ltd (VINEETLAB) reported revenue of ₹75 crore, net profit of ₹-20 crore and earnings per share of ₹-10.52. That compares with revenue of ₹151 crore and net profit of ₹1 crore in Mar 2024. Figures are standalone, as filed with the exchanges.
In the quarter ended Dec 2025, revenue was ₹15.65 crore and net profit ₹0.85 crore (standalone).
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 243 | 191 | 212 | 151 | 75 |
| Net profit (₹ cr) | 2 | 7 | 1 | 1 | -20 |
| EPS (₹) | 0.93 | 3.46 | 0.65 | 0.54 | -10.52 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | -26.80% | -50.20% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 5.98% of Vineet Laboratories Ltd (VINEETLAB) (down 6.48 pp QoQ), foreign institutional investors (FII) hold 0.36%. Market capitalisation was ₹61 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2021.
Largest disclosed public shareholders in Mar 2026: ARJUN AGGARWAL 11.35%, RAJESH PODDAR 2.15%, PALLOLI RAMA CHANDRA REDDY 1.86%, ISWARYA GAJJALA 1.62%, Sudha Madhu Sudhan Reddy 1.61%, ANASUYA GORLA 1.58%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 5.98% | - | 0.36% | - | 94.02% |
| Dec 2025 | 12.46% | - | - | - | 87.54% |
| Sep 2025 | 15.89% | - | - | - | 84.11% |
| Jun 2025 | 29.26% | - | - | - | 70.74% |
| Mar 2025 | 35.85% | - | - | - | 64.15% |
| Dec 2024 | 35.85% | - | - | - | 64.15% |
| Sep 2024 | 36.07% | - | 0% | - | 63.93% |
| Jun 2024 | 37.5% | - | - | - | 62.5% |